Introduction
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after kidney transplant (KTx). The incidence of PTLD has increased since the introduction of newer immunosuppressive drugs [1, 2] and is now the main post-transplant malignant disease in pediatric and the second most prevalent in adult recipients [3] . The incidence of PTLD reaches 1-2% [4] in kidney recipients, up to 20-fold higher than in the non-transplanted population [2, 3, 5] . Treatment involves mainly immunosuppression reduction among other measures, however, mortality rate remains ∼40% in kidney recipients [4] . In the majority of PTLD cases, tumor cells are EBV+. Epstein-Barr virus (EBV) may induce malignant transformation of B lymphocytes with subsequent lymphoproliferation and therefore is recognized as an important risk factor for PTLD. As in other post-transplant malignancies, immunosuppressive drugs impair immune surveillance against tumor cells increasing the risk of developing malignancies when compared to the general population [6, 7] .
In immunocompetent EBV-infected individuals, the virus is latent in cells of the reticuloendothelial system. Transplant immunosupression may allow activation, proliferation and spread of the virus among B lymphocytes increasing the chance of developing PTLD. By contrast, primary EBV infection after a solid organ transplant is likely to result in higher viral loads when compared to EBV reactivation and an increased chance of developing PTLD [8] . At 5, 18 and 40 years of age, about 50, 20 and 5-10% of the general population, respectively, have not been infected with EBV [9, 10] , exposing them to the risk of primary EBV infection after receiving an organ from an EBV seropositive donor [11] . Seronegative recipients who receive a seronegative organ may remain uninfected but may be infected post-transplant.
We examined the risks for PTLD and death according to the recipient-(R) and donor-(D) paired EBV serostatus at the time of KTx in the USA, stratified by donor type [deceased donor (DD) and living donor (LD)]. Given the differences in EBV status, we performed a secondary analysis in pediatric and adult KTx recipients. Our study is unique in comparing the impact of transplanting an EBV+ or EBV− organ into an EBV− adult or pediatric recipient on PTLD incidence. This information may be useful to indicate preventive strategies and interventions to diminish PTLD incidence in KTx.
Materials and methods

Study population
The Organ Procurement Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) database as of 3 September 2010 was used in this study. UNOS began collecting information on recipient EBV serology since 1994, on the incidence of PTLD since 1999 and on EBV serostatus for LD and DD recipients since 1999 and 2006, respectively. Primary kidney-only recipients transplanted between the years 2000-2009 were identified and were further divided according to donor type (DD or LD) and EBV recipient-and donor-paired serostatus. Recipients were considered EBV seropositive if the serologic test for IgG or IgM was positive, and seronegative if IgG was negative. Donors were considered seropositive if the serologic test for IgG, or IgM or a DNA test were positive, and seronegative if IgG or DNA were negative. Recipients not tested, with unknown serology or missing values to EBV serostatus as well as EBV-negative recipients with donors with no information for EBV serostatus were excluded from the main analysis. The study groups were as follows: R+ (recipient EBV positive, reference); D+/R− (an EBV-positive donor with an EBV-negative recipient) and D−/R− (an EBV-negative donor with an EBV-negative recipient). Detailed information on cohort formation is depicted in Figure 1 .
Statistical analysis
DD and LD cohorts were analyzed separately due to the different time when UNOS started collecting serology information. LD transplants were followed up to 10 years and DD transplants up to 4 years. Recipients' baseline characteristics were compared using chi-square test or Fisher's exact tests for categorical variables. The results are presented as median or proportions. Risks of PTLD, death and kidney failure were compared. The incidence for PTLD was estimated using PTLD-free survival. Patients were followed until PTLD diagnosis, graft failure or death. The Kaplan-Meier product-limit method was used to generate survival curves and Cox regression was used to examine risks. PTLD incidence hazard ratios (HRs) were computed after censoring for death or kidney graft failure. The proportional hazards assumption was tested for variables in the models using time-varying covariates and did not indicate serious violations to the proportional hazards assumptions. Recipient age, race, gender, panel of reactive antibodies, human leukocyte antigen mismatch, single immunosuppressive drugs in use at discharge, induction agents, cytomegalovirus (CMV) and hepatitis C serostatus, donor type and year of transplant (categorized as eras) were evaluated as covariates, those with a P-value ≤0.1 in the univariate analysis were included in the multivariate model. The variables related to R/D EBV serostatus were included in the model. Time to death or to graft failure after PTLD diagnosis was also examined in each study group; in this case, PTLD diagnosis date was used as the index date. Risk factors for PTLD were also examined specifically in the D+/R− transplants. PTLD incidence was reported in percent and in 1000 person-years; risks were expressed as HRs with their 95% confidence intervals (CIs). Associated P-values were two tailed and P-values <0.05 were considered significant. STATA version 11 (Statacorp, College Station, TX) was used in all statistical analysis. Table 1 shows the characteristics of each study group. Eighty-six percent (3216/3739) and 75% (3278/4391) of the DD and LD EBV− recipients, respectively, were adults. However, when examining EBV serostatus prevalence by age, EBV-negative serostatus was higher in pediatric patients [36% (523/1448) and 45% (1113/2459) in DD and LD, respectively] than in adult recipients [13% (3246/24118) and 9.9% (3278/33278) in DD and LD, respectively]. EBV− recipients received less induction than R+, which was mainly determined by the use of less thymoglobulin and alemtuzumab among EBV− recipients.
Results
PTLD incidence in recipients with known EBV serostatus across the years
Baseline characteristics
Incidence and risk of PTLD
The incidence of PTLD was higher in R− compared to R + in both LD and DD transplants (Figure 3 ). When PTLD incidence was compared between both groups of EBV− recipients, the incidence in the D+/R− group was higher than in the D−/R− group. However, it was only significant in LD transplants that had a higher number of individuals and a longer follow up, characteristics that allow a more robust comparison.
The risks of PTLD are shown in Table 2 . After controlling for recipient age, race, pre-transplant CMV serostatus and induction agent used, an EBV-negative serostatus was the most significant risk factor for PTLD. The risk of PTLD in EBV− recipients increased 1.8-fold in DD (3.49-6.33) and 2.0-fold in LD (2.50-5.15) if the donor was EBV+ compared with an EBV− donor (R+ as reference). Other covariates associated with increased risk of PTLD can also be found in Table 2 . Not significant but noteworthy was a trend toward an increased risk when using thymoglobulin as an induction agent (adjusted HR 1.84, 95% CI 0.96-3.52, P = 0.06) compared with no induction use in DD recipients.
Risk factors of PTLD in D+/R− transplants (considering a follow-up of 3 years) were examined. In DD recipients, the risk of PTLD was increased by thymoglobulin (HR 5.8, 95% CI, 1.57-17.8, P = 0.007) or interleukin 2 receptor antibodies (HR 6.0, 95% CI, 1.74-20.7, P = 0.004) but not to alemtuzumab (HR 1.09, 95% CI 0.11-10.6, P = 0.94) use versus no induction use and in Caucasians (HR 2.52, 95% CI, 1.23-5.13, P = 0.001) versus other ethnicities. A trend toward decreased risk was seen in transplant year 2007-2009 (HR 0.50, 95% CI, 0.24-1.04, P = 0.07) when compared to [2004] [2005] [2006] . In LD recipients, the risk of PTLD was increased in pediatric recipients (HR 2.98; 95% CI, 1.46-6.06; P = 0.003) when compared to those between 40 and 60 years, and in CMV R− (HR 2.13, 95% CI, 1.11-4.11, P = 0.02) when compared to CMV R+.
Patient survival and risk for death
Univariate or multivariate models for DD and LD recipients according to EBV serostatus did not show EBV Fig. 1 . Flowchart of the cohort selection. The numbers in the bottom boxes correspond to the study cohorts and the population in which risk for PTLD was examined, as seen in Tables 2 and 3. serostatus as an independent risk factor for overall cause of death or graft failure.
Incidence and risk of PTLD in pediatric and adults recipients
Follow-up was limited to 3 years, as data of EBV serostatus in DD were available starting in 2006 and recipients were followed up to 2010. In pediatric recipients, PTLD incidence was higher in the first year after transplant and the slope of the Kaplan-Meier curve was similar for D +/R− and D−/R− recipients in both DD and LD ( Figure 4A and B) . In adults, PTLD incidence was higher in D+/R− when compared to R−/D−, however, significance was reached only in LD recipients (P < 0.001) ( Figure 4C and D) . PTLD incidence and adjusted risk of PTLD in R+, D+/R− and D−/R− transplants according to donor type (DD and LD) and recipient age ( pediatric and adult) are shown in Table 3 . In adults, the risks of PTLD were 2-or 3-fold higher in DD or LD recipients, respectively, when EBV− recipients received a D+ instead of a D− organ, while in pediatric recipients they were almost the same.
Discussion
In developed nations, EBV-naive individuals are found until the fourth decade of life increasing the pool of EBV − adult transplant candidates [12] . In our cohort, 86 and 75% of the EBV− recipients of DD and LD groups were adults, respectively. Of those, some may receive an EBV − organ and may not acquire the virus after transplant. However, EBV− adults who received an EBV+ organ will probably develop EBV infection and have their risk of PTLD increased. We found that in adults, if an EBV D −/R− transplant were performed instead of a D+/R− transplant, the overall PTLD incidence would potentially reduce from 11.2 to 7.23 per 1000 person-years, which represents a 35% reduction in PTLD cases in DD transplants and from 10.49 to 6.02 per 1000 person-years, a 42% reduction in LD transplants.
Our findings raise discussion on the potential advantage of allocation priority of an EBV− organ to an EBV− adult recipient. A recipient with PTLD is potentially fated to graft failure or a lethal outcome and this decision may benefit part of the EBV− adult recipients by reducing PTLD incidence. This is not a definitive solution as the numbers of EBV− recipients may supplant the number of EBV− organs and not all EBV− recipients would be able to receive an EBV− organ or wish to wait longer for a transplant. Moreover, it would not affect the incidence of the fewer number of PTLD cases that are not associated with EBV infection. This criterion may introduce one more condition to the already uneasy organ allocation process but may succeed to diminish PTLD incidence in adults. As matching EBV− donors to EBV− adults is not a perfect solution for preventing PTLD, more emphasis should be given on surveillance studies and on the role of preemptive treatment in adult population. New EBV antiviral agents (e.g. maribavir) [13, 14] may be effective against EBV and immunosuppressive drugs may be titrated early to control viral replication with resulting decrease in PTLD development. A different scenario was noted in pediatric transplants, where PTLD incidence of D−/R− was very similar to that in the D+/R− group, which may be explained by an increased chance of EBV-pediatric recipients to acquire EBV after transplant from other people. A D+/R− transplant instead of a D−/R− in pediatric recipients contributed only to an increase in overall PTLD incidence by 13 and 0%, in DD and LD transplants, respectively. The closest PTLD risk between D+/R− and D−/R− pediatric transplants, the increased risk of these two groups when compared to R+, and the higher prevalence of EBV-negative serostatus indicates that the most desirable intervention in this population for PTLD prevention would be the development of vaccines against EBV. Rees et al. [12, 15] recently demonstrated that vaccination against the EBV glycoprotein 350 was able to produce neutralizing antibody titers in chronic kidney disease children awaiting transplantation. However, titers declined rapidly and may have a limited effect in the post-transplant period. Research in this field is incipient, but promising [16, 17] and LD recipients risk was calculated for a maximum of 10 years follow-up. Reference groups were: R+ for EBV serostatus; age 40-60 years for recipient age; R+ for CMV serostatus and other races for race. Numbers in bold represent significant values. *P < 0.05, ** P < 0.001.
should be encouraged. Alternatively, surveillance and preemptive treatment have been recommended in pediatric EBV-negative recipients [18, 19] .
Also in pediatric transplant, the incidence of PTLD was much higher in EBV recipients receiving a DD kidney, reaching 15-and 17-fold higher, respectively, for EBV− a Risk and incidence were calculated based on a 3-year follow-up. PY, person-years; u, unadjusted; a, adjusted. Covariates included in the adjusted results were: in DD pediatric recipients, recipient age, human leukocyte antigen (HLA) mismatch, gender and immunossupression at discharge; in DD adult recipients, induction agent type, peak reactive antibodies (PRA), HLA mismatch, immunossupression at discharge, year of transplant, hepatitis C virus (HCV) recipient serostatus, recipient race, recipient gender and pre-transplant dialysis duration and in pediatric and adult LD transplants, induction agent type, PRA, HLA mismatch, immunossupression at discharge, year of transplant, CMV donor and recipient serostatus, HCV recipient serostatus, recipient race, recipient gender and pre-transplant dialysis duration. Numbers in bold represent significant values. *P < 0.05, **P < 0.001.
and EBV+ donor transplants when compared to EBV+ DD recipients. In LD pediatric transplants risks were lower than DD between 7.7-and 6.9-fold higher, respectively, for D−/R− and D+/R− transplants. Our findings in pediatric LD recipients are in line with a previous prospective randomized trial in pediatric kidney recipients that reported a 7.7-fold increase in risk of PTLD in EBV D+/R− transplants. However, this prospective steroid withdrawal trial was stopped early (at 2 years), and the majority of the recipients (70%) included in the study received an LD organ [20] . Our results indicate that the risk of PTLD in pediatric DD transplants may be even higher, when compared to LD. We speculate that the higher risk of PTLD in DD versus LD may be related with more intense immunosuppression and higher rate of rejection episodes that require treatment with induction agents in the DD group combined with a higher prevalence of EBV − serostatus in the pediatric population. Our finding of recent trend toward a reduction in overall PTLD incidence is a consequence of a small but significant reduction in PTLD incidence among EBV− recipients. This is a new observation in KTx since previous studies reported an increase in PTLD incidence associated with the use of calcineurin inhibitors and T-cell depleting antibodies [21] . The recent trend in PTLD incidence decrease may be explained by measures adopted in renal transplant in the last years. The first measure consisted of use of lower immunosuppressive maintenance drug doses and a more rational use of induction agents to diminish complications related with over-immunosupression (e.g. viral infections, drugs side effects as new onset diabetes after transplant and malignancies). A possible second explanation is the use of prophylactic treatment or routine surveillance with preemptive treatment for other viruses, including CMV and BK virus. Koleilat et al. [22] have shown that surveillance for BK virus with subsequent immunosuppression reduction has diminished CMV and EBV post-transplant infections, and Funch et al. [23] showed that the risk of PTLD was reduced with ganciclovir and acyclovir prophylaxis. A third measure has been the surveillance of EBV viral load and pre-emptive treatment to control EBV replication performed in some pediatric centers with reported successful reduction in the number of PTLD cases [18] .
Limitations of our study included those related to the nature of retrospective analyses. Only cases with complete records for recipient and donor EBV serostatus were used in the analysis resulting in exclusion of a significant number of patients. We could not correlate outcomes with intensity of immunosuppression as UNOS do not collect dosage or blood levels of immunosuppressive drugs. We did not examine the association of CMV prophylaxis or treatment with PTLD development. UNOS also does not provide EBV status of the PTLD lesion; therefore, we could not distinguish negative from positive EBV PTLD lesions.
In conclusion, using US KTx database, we found that EBV-negative adult recipients were at an increased risk of developing PTLD when receiving an organ from an EBVpositive donor. In adults, a D+/R− transplant instead of a D−/R− has contributed to an increase in overall PTLD incidence by 35 and 42%, while in pediatric recipients by 13 and 0%, in DD and LD transplants, respectively.
